AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26387028 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with standard method according to ACC/AHA guidelines in UAP/NSTEMI 2007.
Number of subjects: 126
Study 26387028 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading-dose rosuvastatin therapy.
Number of subjects: 126
Study 23261174 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 100
Study 23261174 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin/ezetimibe 10/10 mg
Number of subjects: 100
Study 21627526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine B (2 mL doses, n = 12)
Number of subjects: 51
Study 21627526 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental bacterin (n = 12)
Number of subjects: 51
Study 21627526 — intervention group
Group type: COMPARATOR
Intervention: Vaccine A (5 mL doses, n = 13)
Number of subjects: 51
Study 21627526 — intervention group
Group type: COMPARATOR
Intervention: Sham vaccine (n = 14)
Number of subjects: 51
Study 19378885 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC) starting 30 minutes before and continuing 10 minutes after an invasive procedure
Number of subjects: 50
Study 19378885 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 50
Study 17225048 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups A, B, C (iodine dose 450-600 mg/kg, injection duration 30 s)
Number of subjects: 20
Study 17225048 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (iodine dose 450 mg/kg, injection duration 25 s)
Number of subjects: 20
Study 15321810 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soy diet (104 +/- 24 mg total isoflavones/d)
Number of subjects: 76
Study 15321810 — intervention group
Group type: COMPARATOR
Intervention: Low-soy diet (0.54 +/- 0.58 mg total isoflavones/d)
Number of subjects: 76
Study 15321810 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soy diet
Number of subjects: 76
Study 11463411 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin 40 U
Number of subjects: 200
Study 11463411 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine 1 mg
Number of subjects: 200
Study 9512230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI) in patients with previous failed fertilization or low fertilization rate
Number of subjects: 284
Study 9512230 — intervention group
Group type: COMPARATOR
Intervention: Intracytoplasmic sperm injection (ICSI) in patients with primary male factor
Number of subjects: 284
Study 7518728 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment for 4 months
Number of subjects: 21
Study 7518728 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment for 4 months in males
Number of subjects: 21
Study 7518728 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment for 4 months in females
Number of subjects: 21
Study 3177228 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120 to 180 mg twice daily, mean dose 307 mg/day)
Number of subjects: 23
Study 3177228 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 23
Study 3177228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31785275 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic clipping closure
Number of subjects: 155
Study 31785275 — intervention group
Group type: COMPARATOR
Intervention: Nonclosure
Number of subjects: 155
Study 30499685 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating bone-specific alkaline phosphatase (BALP) levels
Number of subjects: 156
Study 30499685 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein, dialysis vintage, and BALP
Number of subjects: 156
Study 30499685 — intervention group
Group type: EXPERIMENTAL
Intervention: BALP levels
Number of subjects: 156
Study 26887576 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua-cycling (two 45-min sessions weekly for 12 weeks)
Number of subjects: 0
Study 26887576 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study 26259989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab half-standard dosing (HSD)
Number of subjects: 110
Study 26259989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab standard dosing (SD)
Number of subjects: 110
Study 26259989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 26259989 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 110
Study 23786937 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splints for 1 month
Number of subjects: 36
Study 23786937 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-occluding palatal) splints
Number of subjects: 36
Study 23786937 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splints
Number of subjects: 36
Study 21178616 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 0
Study 21178616 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose therapy (including bortezomib and immune-modulatory drugs)
Number of subjects: 0
Study 21178616 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring using NT-proBNP, cTn, and FLC
Number of subjects: 0
Study 19032132 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone PR/Naloxone PR
Number of subjects: 322
Study 19032132 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone PR
Number of subjects: 322
Study 17220048 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of losartan (100 mg)
Number of subjects: 24
Study 17220048 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of losartan (100 mg)
Number of subjects: 24
Study 17220048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 14694935 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab prophylaxis (5 monthly intramuscular injections at 15 mg/kg)
Number of subjects: 0
Study 9428859 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 45
Study 9428859 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 45
Study 9428859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 45
Study 9428859 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 45
Study 8595788 — intervention group
Group type: COMPARATOR
Intervention: Tiagabine (TGB) hydrochloride as add-on therapy
Number of subjects: 2261
Study 8595788 — intervention group
Group type: COMPARATOR
Intervention: Tiagabine (TGB) hydrochloride
Number of subjects: 2261
Study 2529893 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ketoconazole cream
Number of subjects: 50
Study 2529893 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone cream
Number of subjects: 50
Study 1107360 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine succinate (40-80 mg daily)
Number of subjects: 43
Study 1107360 — intervention group
Group type: COMPARATOR
Intervention: Trifluoperazine (20-50 mg daily)
Number of subjects: 43
Study 1107360 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine succinate
Number of subjects: 43
Study 1107360 — intervention group
Group type: COMPARATOR
Intervention: Trifluoperazine
Number of subjects: 43
Study 29982805 — intervention group
Group type: EXPERIMENTAL
Intervention: depatuziuzumab mafodotin (0.5-1.5 mg/kg) + temozolomide (150-200 mg/m2)
Number of subjects: 60
Study 29138547 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg tiotropium for 4 weeks
Number of subjects: 30
Study 29138547 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 μg indacaterol for 4 weeks
Number of subjects: 30
Study 29138547 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of tiotropium and indacaterol for 4 weeks
Number of subjects: 30
Study 23998376 — intervention group
Group type: EXPERIMENTAL
Intervention: SAAF-T intervention
Number of subjects: 473
Study 21447368 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser irradiation (L)
Number of subjects: 130
Study 21447368 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride (AmF/NaF gel) application (F)
Number of subjects: 130
Study 21447368 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser prior to fluoride (LF)
Number of subjects: 130
Study 21447368 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride prior to laser (FL)
Number of subjects: 130
Study 21447368 — intervention group
Group type: COMPARATOR
Intervention: Non‐treated control (C)
Number of subjects: 130
Study 19416526 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (4 ng/kg) administered intravenously
Number of subjects: 22
Study 19416526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19416526 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-67657 (p38 MAP kinase inhibitor) administered 30 minutes before LPS infusion
Number of subjects: 22
Study 19416526 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic patients (21 patients)
Number of subjects: 22
Study 17156221 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium
Number of subjects: 338
Study 17156221 — intervention group
Group type: COMPARATOR
Intervention: cisatracurium
Number of subjects: 338
Study 15124707 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (allo-SCT)
Number of subjects: 0
Study 15124707 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell allografting from alternative donors
Number of subjects: 0
Study 11435335 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression
Number of subjects: 84
Study 11435335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 9681666 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (40 mg oral or intravenous for healthy subjects; 20 mg oral for patients with renal insufficiency or hepatic cirrhosis)
Number of subjects: 3
Study 9681666 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg oral for patients with hepatic cirrhosis)
Number of subjects: 3
Study 8042927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine (ergoloid mesylates)
Number of subjects: 47
Study 8042927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 1955122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (0.3 mg/kg PO t.i.d.)
Number of subjects: 20
Study 1955122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1955122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 20
Study 772425 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 54
Study 772425 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 54
Study 772425 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 54
Study 31734696 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV intravenous immunoglobulin (IVIG)
Number of subjects: 61
Study 31734696 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IVIG)
Number of subjects: 61
Study 31734696 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV IVIG
Number of subjects: 61
Study 30597112 — intervention group
Group type: EXPERIMENTAL
Intervention: lemborexant 2.5 mg
Number of subjects: 48
Study 30597112 — intervention group
Group type: EXPERIMENTAL
Intervention: lemborexant 5 mg
Number of subjects: 48
Study 30597112 — intervention group
Group type: EXPERIMENTAL
Intervention: lemborexant 10 mg
Number of subjects: 48
Study 30597112 — intervention group
Group type: COMPARATOR
Intervention: zopiclone 7.5 mg
Number of subjects: 48
Study 30597112 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study 28544807 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide for 1 year
Number of subjects: 24
Study 28544807 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 24
Study 25378034 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% oral glucose solution
Number of subjects: 80
Study 23628109 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo culture in an atmosphere of 5.5% CO2, 6% O2, and 88.5% N2
Number of subjects: 1125
Study 23628109 — intervention group
Group type: COMPARATOR
Intervention: 5.5% CO2 in air
Number of subjects: 1125
Study 21305270 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSU 10 mg/day starting 5 days before the infusion of ZOL for a total period of 11 days
Number of subjects: 28
Study 21305270 — intervention group
Group type: COMPARATOR
Intervention: No ROSU treatment
Number of subjects: 28
Study 21305270 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSU 10 mg/day
Number of subjects: 28
Study 19824553 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B Exceed toothbrush
Number of subjects: 41
Study 19824553 — intervention group
Group type: COMPARATOR
Intervention: Asian Colgate 360 degrees toothbrush
Number of subjects: 41
Study 16886588 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with DM1
Number of subjects: 58
Study 16886588 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58
Study 15999214 — intervention group
Group type: EXPERIMENTAL
Intervention: n-butyl-(2)-cyanoacrylate (NBCA)
Number of subjects: 64
Study 15999214 — intervention group
Group type: EXPERIMENTAL
Intervention: n-butyl-(2)-cyanoacrylate + methacryloxysulfolane (NBCA-MS)
Number of subjects: 64
Study 15999214 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger than 18 years
Number of subjects: 64
Study 15999214 — intervention group
Group type: EXPERIMENTAL
Intervention: Older than 18 years
Number of subjects: 64
Study 15999214 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with vessel wall perforation
Number of subjects: 64
Study 15999214 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without vessel wall perforation
Number of subjects: 64
Study 14572489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligon Vantex silver central venous catheter (CVC)
Number of subjects: 206
Study 14572489 — intervention group
Group type: COMPARATOR
Intervention: Standard polyurethane central venous catheter (CVC)
Number of subjects: 206
Study 10624955 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic phenomena
Number of subjects: 0
Study 10624955 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual system mechanisms
Number of subjects: 0
Study 7717631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Number of subjects: 82
Study 2115503 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis regimen consisting of polymyxin E, tobramycin, and amphotericin B
Number of subjects: 200
Study 2115503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 10248151 — intervention group
Group type: COMPARATOR
Intervention: Information booklet provided to patients on the experimental ward and control ward.
Number of subjects: 0
Study 10248151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective therapeutic skills training for staff nurses on the experimental ward.
Number of subjects: 0
Study 10248151 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive and informative talk with a trained nurse on the experimental ward.
Number of subjects: 0
Study 30519955 — intervention group
Group type: EXPERIMENTAL
Intervention: External cold and a vibrating device
Number of subjects: 60
Study 30519955 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (1.8 ml of 2% lidocaine with 1:100,000 adrenaline)
Number of subjects: 60
Study 28017199 — intervention group
Group type: EXPERIMENTAL
Intervention: Active left DLPFC stimulation
Number of subjects: 10
Study 28017199 — intervention group
Group type: EXPERIMENTAL
Intervention: Active right PPC stimulation
Number of subjects: 10
Study 28017199 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study 26260081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use disorder (CUD)
Number of subjects: 133
Study 26260081 — intervention group
Group type: EXPERIMENTAL
Intervention: Recency of cannabis use
Number of subjects: 133
Study 26260081 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of cannabis use
Number of subjects: 133
Study 26260081 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose of cannabis consumption
Number of subjects: 133
Study 23828291 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training
Number of subjects: 19
Study 23828291 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 19
Study 23828291 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 19
Study 21957588 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymogen preparation administered by intranasal instillation of 100 mg once a day for 7 days before surgery
Number of subjects: 0
Study 21957588 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (placebo) administered in the same scheme
Number of subjects: 0
Study 19703279 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 5 IU bolus and 40 IU infusion
Number of subjects: 2000
Study 19703279 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin 5 IU bolus and placebo infusion
Number of subjects: 2000
Study 17367495 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF 4227 (5-400 mg single doses)
Number of subjects: 100
Study 17367495 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF 4227 (5-100 mg multiple doses)
Number of subjects: 100
Study 17367495 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF 4227 (5 and 10 mg)
Number of subjects: 100
Study 14702440 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) at 24 micro g/kg per hour for 96 hours (part 2)
Number of subjects: 83
Study 14702440 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) at escalating doses of 6, 12, 24, and 36 micro g/kg per hour for 6 hours (part 1)
Number of subjects: 83
Study 11736869 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg twice daily for 15 days
Number of subjects: 10
Study 11736869 — intervention group
Group type: COMPARATOR
Intervention: Theophylline 200 mg twice daily alone for 8 days
Number of subjects: 10
Study 9243685 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg.kg‐1
Number of subjects: 90
Study 9243685 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0.25 mg.kg‐1 with droperidol 0.25 mg.kg‐1
Number of subjects: 90
Study 9243685 — intervention group
Group type: COMPARATOR
Intervention: Trimeprazine 2 mg.kg‐1
Number of subjects: 90
Study 9243685 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam or diazepam‐droperidol
Number of subjects: 90
Study 8301808 — intervention group
Group type: EXPERIMENTAL
Intervention: GI priming with mother's milk (n = 7)
Number of subjects: 47
Study 8301808 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition alone (n = 21)
Number of subjects: 47
Study 8301808 — intervention group
Group type: EXPERIMENTAL
Intervention: GI priming with infant formula (n = 19)
Number of subjects: 47
Study 3718367 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fenoterol
Number of subjects: 12
Study 3718367 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol
Number of subjects: 12
Study 3718367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31094260 — intervention group
Group type: EXPERIMENTAL
Intervention: HAW (water ad libitum)
Number of subjects: 20
Study 31094260 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat acclimation
Number of subjects: 20
Study 31094260 — intervention group
Group type: COMPARATOR
Intervention: HANW (no fluid allowed)
Number of subjects: 20
Study 31462990 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation
Number of subjects: 200
Study 31462990 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 200
Study 28460597 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Ankle Foot Orthosis (AFO)
Number of subjects: 10
Study 28460597 — intervention group
Group type: COMPARATOR
Intervention: Inactive Ankle Foot Orthosis (AFO)
Number of subjects: 10
Study 26545272 — intervention group
Group type: EXPERIMENTAL
Intervention: Boil-and-bite (BB) mouthpiece
Number of subjects: 16
Study 26545272 — intervention group
Group type: COMPARATOR
Intervention: No mouthpiece (NM)
Number of subjects: 16
Study 26545272 — intervention group
Group type: COMPARATOR
Intervention: Ethylene vinyl acetate (EVA) custom mandibular mouthpiece
Number of subjects: 16
Study 26545272 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene (Poly) custom mandibular mouthpiece
Number of subjects: 16
Study 23620935 — intervention group
Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion with spontaneous heating bags, applied for 12 hours once a day.
Number of subjects: 120
Study 23620935 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (smectite powder and live combined bifidobacterium and lactobacillus tablets), orally administered.
Number of subjects: 120
Study 21623600 — intervention group
Group type: EXPERIMENTAL
Intervention: sulodexide 75 mg daily
Number of subjects: 77
Study 21623600 — intervention group
Group type: EXPERIMENTAL
Intervention: sulodexide 150 mg daily
Number of subjects: 77
Study 21623600 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 77
Study 19458014 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal iron (n = 48)
Number of subjects: 152
Study 19458014 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified cereal (n = 45)
Number of subjects: 152
Study 19458014 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 59)
Number of subjects: 152
Study 16446376 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate 2000/125 mg twice daily
Number of subjects: 566
Study 16446376 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 875/125 mg three times daily
Number of subjects: 566
Study 15153926 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational feedback intervention
Number of subjects: 37
Study 15153926 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 37
Study 11897014 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, one-time tobacco-use prevention intervention
Number of subjects: 28